Skip to main content

Advertisement

Log in

Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma

  • EPS Proceedings
  • Published:
Endocrine Pathology Aims and scope Submit manuscript

Abstract

Discerning malignancy in resected adrenocortical neoplasms can pose diagnostic difficulty. Macroscopic examination is the first important step toward diagnosis and should include accurate measurement of weight and dimension of the specimens and description of the cut surface of the tumors. It is also important to sample the specimens for histological diagnosis near foci of hemorrhage and/or necrosis. Histological scoring systems evaluating multiple parameters, especially the criteria of Weiss, have been shown to be reliable in differential diagnosis between adrenocortical adenoma and carcinoma. A tumor is defined as adrenocortical carcinoma when three or more of the following criteria are met; (1) high nuclear grade, (2) mitotic rate six or more per 50 high power fields, (3) atypical mitosis, (4) clear cells less than 25%, (5) a diffuse architecture pattern in more than one-third of the tumor, (6) confluent necrosis, (7) venous invasion, (8) sinusoidal invasion, and (9) capsular invasion. The criteria are relatively straightforward and considered the most effective standard for diagnosis of adrenocortical malignancy. However, great care should be taken in applying the criteria to histological evaluation of two relatively rare and peculiar adrenocortical tumors, adrenocortical oncocytoma and pediatric adrenocortical neoplasms. At this juncture, ancillary biological or molecular markers are of little practical value in terms of differential diagnosis between adrenocortical adenoma and carcinoma but tumors with MIB1 or Ki-67 labeling index more than 2.5 may be considered malignant. Prognostic markers of adrenocortical carcinoma have not been established other than complete respectability of the tumor. There are also no surrogate markers for predicting response to therapy with Mitotane, an adrenolytic agent. It sometimes is important for surgical pathologists to differentiate adrenocortical carcinoma from metastatic malignancies of other sites. An immunohistochemical evaluation of adrenal 4 binding protein (Ad4BP) or SF-1, a transcription factor of all steroidogenesis, can aid in this differential diagnosis because nuclear immunoreactivity for this transcription factor is relatively specific to steroid producing cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Sasano N. Functional pathology of adrenocortical endocrine disorders. Trans Soc Pathol Jpn 64:31–54, 1975.

    Google Scholar 

  2. Sasano N, Sasano H. The adrenal cortex. In: Kovacs K, Asa SL, eds. Functional endocrine pathology. Oxford: Blackwell, 1998, 546–584.

    Google Scholar 

  3. Gandour, MJ, Grizzle WE. A small adrenocortical carcinoma with aggressive behavior. An evaluation of criteria for malignancy. Arch Pathol Lab Med 110:1076–1079, 1986.

    PubMed  CAS  Google Scholar 

  4. Hough AJ, Hollifield, JW, Page DL, Hartmann WH. Prognostic factors in adrenal cortex tumors: a mathematical analysis of clinical and morphological data. Am J Clin Pathol 72:390–399, 1979.

    PubMed  CAS  Google Scholar 

  5. Weiss LM. Comparable histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 8:163–169, 1984.

    Article  PubMed  CAS  Google Scholar 

  6. Weiss LM, Medeiros LJ, Vickery AL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 13:202–206, 1989.

    Article  PubMed  CAS  Google Scholar 

  7. Sasano H, Suzuki T, Sano T, et al. Adrenocortical oncocytoma–a true nonfunctioning adrenocortical tumor. Am J Surg Pathol 15:949–956, 1991.

    Article  PubMed  CAS  Google Scholar 

  8. Hoang MP, Ayala AG, Albores-Saavedra J. Oncocytic adrenocortical carcinoma: a morphologic, immunohistochemical and ultrastructural study of four cases. Mod Pathol 15:973–978, 2002.

    Article  PubMed  Google Scholar 

  9. Wieneke JA, Thompson LDR, Heffess CS Adrenal cortical neoplasms in the pediatric population. A clinicopathological and immunophenotypic analysis of 83 patients, Am J Surg Pathol 77:867–881, 2003.

    Article  Google Scholar 

  10. Lack EE, Mulivihil JJ, Travis WD, et al. Adrenocortical neoplasms in the pediatric and adolescent age group. Clinicopathological study of 30 cases with emphasis on epidemiological and prognostic factors. Pathol Annu 27:1–53, 1992.

    PubMed  Google Scholar 

  11. Mickalkiexicz EL, Sandrini R, Figueriredo B, et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the international pediatric adrenocortical registry. J Clin Oncol 22:838–845, 2004.

    Article  Google Scholar 

  12. Stojadinovic, A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 15:941–950, 2002.

    Article  Google Scholar 

  13. Stratakis CA. Genetics of adrenocortical tumors: gatekeepers, landscapers and conductors in symphony. Trends Endocrinol Metab 14:404–410, 2003.

    Article  PubMed  CAS  Google Scholar 

  14. Sidhu S, Gicquel C, Bambach CP, et al. Clinical and molecular aspects of adrenocortical tumorigenesis. ANZ J Surg 73:727–738, 2003.

    Article  PubMed  Google Scholar 

  15. Iino K, Sasano H, Yabuki N, et al. DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas. Mod Pathol 10:901–907, 1997.

    PubMed  CAS  Google Scholar 

  16. Nakazumi H, Sasano H, Iino K, Ohashi Y, Orikasa S. Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms. Mod Pathol 11:1165–1170, 1998.

    PubMed  CAS  Google Scholar 

  17. Martins ACP, Cologna AJ, Tucci S, et al. Clinical features and immunoexpression of p53, MIB-1 and proliferating cell nuclear antigen in adrenal neoplasms. J Urol 173:2138–2142, 2005.

    Article  PubMed  CAS  Google Scholar 

  18. Bernini GP, Moretti A, Viacava, P, et al. Apoptosis control and proliferation marker in human normal and neoplastic adrenocortical tissues. Br J Cancer 86:1561–1565, 2002.

    Article  PubMed  CAS  Google Scholar 

  19. Wachenfeld C, Beuschlein, F, Zwermann O, et al. Discerning malignancy in adrenocortical tumors: are molecular markers useful? Eur J Endocrinol 145:335–341, 2001.

    Article  PubMed  CAS  Google Scholar 

  20. Terzolo M, Boccuzzi A, Bovio S, et al. Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology 57:176–182, 2001.

    Article  PubMed  CAS  Google Scholar 

  21. Krishnamurthy S, Ordonez NG, Shelton TO, et al. Fine-needle aspiration cytology of a case of oncotytic adrenocortical carcinoma. Diagn Cytopathol 22:299–303, 2000.

    Article  PubMed  CAS  Google Scholar 

  22. Sasano H, Shizawa S, Nagura H. Adrenocortical cytopathology. Am J Clin Pathol 104:161–166, 1995.

    PubMed  CAS  Google Scholar 

  23. Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol 169:5–11, 2003.

    Article  PubMed  Google Scholar 

  24. Harrison LF, Gaudin PB, Brennan MF. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 134:181–185, 1999.

    Article  PubMed  CAS  Google Scholar 

  25. Hahner S, Fassnacht M. Mitotane for adreno-cortical carcinoma treatment. Curr Opin Investig Drugs 6:386–394, 2005.

    PubMed  CAS  Google Scholar 

  26. Berruti A, Terzolo M, Pia A, et al. Mitotane associated with etoposide, doxorubicin, and cisplatin in treatment of advanced adrenocortical carcinoma. Italian group study of adrenal cancer. Cancer 83:2194–2200, 1998.

    Article  PubMed  CAS  Google Scholar 

  27. Neville AM, O'Hare MJ. The human adrenal cortex. Berlin, Germany: Springer Verlag, 1982.

    Google Scholar 

  28. Sasano H, Okamoto M, Sasano N. Immuno-histochemical study of human adrenal cortex with mineralo- and glucocorticoid excess. Virchows Arch [A] 413:313–318, 1988.

    CAS  Google Scholar 

  29. Sasano H. Localization of steroidogenic enzymes in adrenal cortex and its disorders. Endocrine J 41:471–482, 1994.

    CAS  Google Scholar 

  30. Sasano H. New approaches in human adrenocortical pathology: assessment of adrenocortical function in surgical specimen of human adrenal glands. Endocr Pathol 3:4–13, 1992.

    Article  Google Scholar 

  31. Tartour E, Caillou B, Tenenbaum F, et al. Immunohistochemical study of adrenocortical carcinoma: predictive value of the D11 monoclonal antibody. Cancer 72:3296–3303, 1993.

    Article  PubMed  CAS  Google Scholar 

  32. Sasano H, Shizawa S, Suzuki T, et al. Transcription factor adrenal 4 binding protein as a marker of adrenocortical malignancy. Hum Pathol 26:1154–1156, 1995.

    Article  PubMed  CAS  Google Scholar 

  33. Takayama K, Sasano H, Fukaya T, et al. Immunohistochemical localization of Ad4-binding protein with correlation to steroidogenic enzyme expression in cycling human ovaries and sex cord stromal tumors. J Clin Endocrinol Metab. 80:2815–2821, 1995.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hironobu Sasano MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sasano, H., Suzuki, T. & Moriya, T. Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma. Endocr Pathol 17, 345–354 (2006). https://doi.org/10.1007/s12022-006-0006-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12022-006-0006-0

Key Words

Navigation